IMPACT ON COMBINATION PRODUCTS AND COMPANION DIAGNOSTICS

July 19, 2019

With the end of the Medical Device Regulation’s (MDR) transition period looming (May 26th, 2020), manufacturers of drug device combination products or companion diagnostics are under heightened time pressure to comply with the new Regulation. Any company manufacturing or distributing these products risks losing European market access unless their products meet the latest regulatory requirements.

Spotlight

Infinity Pharmaceuticals

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.

OTHER WHITEPAPERS
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More
news image

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More
news image

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Read More

Spotlight

Infinity Pharmaceuticals

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.

Events